Fig. 11
From: Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
MS-275 treatment decreased the SP fraction of NB and teratocarcinoma cells. a using Hoechst 33342 dye exclusion, the SP fraction in NT2/D1, SH-SY5Y and SK-N-BE(2) was determined to be 3.32 ± 1.26%, 0.74 ± 0.35% and 0.32 ± 0.11%, respectively. b representative FACs SP profiles for SH-SY5Y control and cells treated with 1.5 μM MS-275, 100nM TSA and 10 μM CDDP. Gating was determined by verapamil negative control. c normalizing for control, 0.75 μM MS-275 reduced the SP fraction significantly (p < 0.0001, p = 0.0098 and p = 0.0237). Similar treatments with 1.5 μM MS-275 also reduced the SP population in NT2/D1, SH-SY5Y and SK-N-BE(2) significantly (p < 0.0001, p = 0.0177 and p < 0.0001). d low nM doses, 0.1 μM HDACi TSA and 0.75 μM MS-275, significantly reduced the SP fraction of both NB lines but greater in SK-N-BE(2), a MYCN amplified cell line (p = 0.0062, p = 0.045 respectively); in contrast highly toxic levels of CDDP did significantly alter the SP fraction (p > 0.05)